There is not one survivor in the world than gives a damn about prognostication. They all want to know EXACT stroke rehab protocols and the efficacy rating of them. Useless. So you are advocating the nocebo effect whereby survivors should live down to their rehab predictions? Like the many times doctors have told patients; 'You won't recover, or walk again'.
Thinking About the Future: A Review of Prognostic Scales Used in Acute Stroke
- Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background: There are many prognostic
scales that aim to predict functional outcome following acute stroke.
Despite considerable research interest, these scales have had limited
impact in routine clinical practice. This may be due to perceived
problems with internal validity (quality of research), as well as
external validity (generalizability of results). We set out to collate
information on exemplar stroke prognosis scales, giving particular
attention to the scale content, derivation, and validation.
Methods: We performed a focused
literature search, designed to return high profile scales that use
baseline clinical data to predict mortality or disability. We described
prognostic utility and collated information on the content, development
and validation of the tools. We critically appraised chosen scales based
on the CHecklist for critical Appraisal and data extraction for
systematic Reviews of prediction Modeling Studies (CHARMS).
Results: We chose 10 primary scales
that met our inclusion criteria, six of which had revised/modified
versions. Most primary scales used 5 input variables (range: 4–13), with
substantial overlap in the variables included. All scales included age,
eight included a measure of stroke severity, while five scales
incorporated pre-stroke level of function (often using modified Rankin
Scale), comorbidities and classification of stroke type. Through our
critical appraisal, we found issues relating to excluding patients with
missing data from derivation studies, and basing the selection of model
variable on significance in univariable analysis (in both cases noted
for six studies). We identified separate external validation studies for
all primary scales but one, with a total of 60 validation studies.
Conclusions: Most acute stroke prognosis
scales use similar variables to predict long-term outcomes and most
have reasonable prognostic accuracy. While not all published scales
followed best practice in development, most have been subsequently
validated. Lack of clinical uptake may relate more to practical
application of scales rather than validity. Impact studies are now
necessary to investigate clinical usefulness of existing scales.
Introduction
Outcomes following a stroke event can range from full
recovery, through varying degrees of disability to death. Given the
subsequent need for intervention planning, resource use, and lifestyle
adjustments, predicting outcome following stroke is of key interest and
importance to patients, their families, clinicians, and hospital
administrators. Various tools exist to assist in estimating
stroke-related prognosis. For example, the ABCD2 score uses clinical
features to predict risk of stroke following transient ischemic attack
(TIA) (1). Although there are criticisms of ABCD2, it is widely used and included in stroke guidelines (2).
Scales for predicting acute stroke outcomes from baseline features are also described in the scientific literature (3–5).
Often prognosis scales report mortality; however, given the disabling
nature of stroke, scales predicting death and/or longer-term disability
may be more useful in the stroke setting (6).
However, these prognostic scales have had limited clinical traction and
have not been incorporated into routine clinical practice (3). There are many plausible reasons why these scales have not been adopted by the stroke community (6).
In an acute setting, scales may be perceived as being too complex to
use or may require information that is not routinely available (for
example, sophisticated neuroimaging) (3).
Clinicians may moreover be concerned that scales are inherently too
generic, and may not provide insight over what the clinician can
conclude based on individual patient factors and clinical gestalt (7).
For many scales, clinicians may simply not be convinced
of their utility or the rigor of the underpinning science. These points
can be addressed by describing the validity of the scales. Issues with
validity could relate to the methodological quality of the initial
derivation of the scale (internal validity) or the generalizability of a
scale to a real-world population (external validity). Robust evidence
of validity requires assessment of the scale in cohorts independent of
the population used to derive that scale (8).
However, In some areas of stroke practice, for example rehabilitation,
it has been demonstrated that independent validation studies are lacking
for many scales (5).
Collating evidence around the quality of the research
that led to development of prognostic scales and also the results of
subsequent validation work could be useful for various stakeholders. For
clinicians it may convince of the utility, or lack of utility, of
certain tools; for researchers it may point to common methodological
limitations that need to be addressed in future work and for policy
developers, if a certain tool has a more compelling evidence base than
others, then this scale may be preferred in guidelines.
Previous reviews have reported that many stroke
prognosis scales have similar properties such as discrimination and
calibration. These reviews also highlight the limited evidence for
external validity of many commonly used stroke scales (9, 10).
Distinguishing an optimal prognostic tool may not be possible based on
psychometric properties alone and factors such as feasibility and
acceptability in the real world setting need to be considered.
We sought to collate and appraise a selection of exemplar
published stroke scales, designed for use in acute care settings. We
used these as a platform to discuss methodological quality of prognostic
scale development, while also considering potential barriers or
facilitators to implementation of the scales in clinical practice.
No comments:
Post a Comment